JAK Inhibitors in the Management of Rheumatoid Arthritis
This CME/CE-accredited CME Snapshot™ series of educational videos has been created for rheumatologists and other clinicians involved in treating patients with rheumatoid arthritis (RA). During each 15-minute activity, two expert rheumatologists focus on a specific aspect of long-term RA management, including practical advice on implementing international treat-to-target guidelines as well as the mechanistic profiles and clinical evidence for therapies designed to inhibit signaling via interleukin-6 (IL-6) or members of the Janus kinase (JAK) family of enzymes. Some of the modules also include 3D-animated elements to illustrate the relationships between the heterogeneous pathophysiologic mechanisms underlying RA and certain targeted biologic or synthetic disease-modifying treatment options.
This activity has been designed to meet the educational needs of rheumatologists and other clinicians involved in the ongoing management of patients with RA.
Upon completion of this activity, participants will be better able to do the following:
- Implement treat-to-target strategies to reflect shared clinical decision making, comprehensive evaluations of RA activity, and other patient-specific factors
Paul Emery, MD, MA, FRCP, FMedSci
Alan J. Kivitz, MD, CPI
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
Paul Emery, MD, MA, FRCP, FMedSci
Consultant/Advisor: AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Samsung Bioepis; Sandoz International GmbH; UCB, Inc.
Speakers’ Bureau: AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Samsung Bioepis; Sandoz International GmbH; UCB, Inc.
Research Grant: AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Samsung Bioepis; Sandoz International GmbH; UCB, Inc.
Alan J. Kivitz, MD, CPI
Consultant/Advisor: AbbVie Inc.; Vertex Pharmaceuticals Incorporated
Non-faculty: Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by independent educational grants from Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education, Dannemiller, and Integritas Communications.
CME Credit (Physicians)
These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates each enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
CE CREDITS (NURSING)
In support of improving patient care, this activity has been planned and implemented by Dannemiller and Elsevier Office of Continuing Medical Education. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this educational activity for 0.25 contact hours.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Dannemiller, Integritas Communications, Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Nursing Contact Hours
- 0.25 Non-physician